Oncolytics Biotech Inc ONCY

US$10 Billion is a typical estimate for a M&A in 2023

[Noteable]

"Les Funtleyder, a healthcare portfolio manager at E Squared Capital Management, said he expected Pfizer would make a series of acquisitions this year. These would likely focus on companies that are typically $10bn or below with products close to being commercialised, he said."

https://www.ft.com/content/ba2cba41-0a13-4251-bbd7-2abeff90433f

[Noteable]

Inflation is a driver for Big Pharma companies like Pfizer, with large cash reserves, to put that cash to work in the form of M&A activites - given the fact that inflation is eroding the purchasing power of Big Pharma's cash reserves and has the effect of increasing the cost of debt financing. Furthermore Big Pharma's patent cliff is another driver that will have global pharma

[Noteable]

The $28bn that Horizon went for last year is undeniably a huge amount of money, but in the biopharma world this is still considered a bolt-on transaction. A relatively quiet couple of years for M&A shows that these tuck-in moves are exactly what large developers are focusing on. Last year’s biggest move however, Amgen’s $28bn bid for Horizon, is also stuck in regulatory limbo, although

[Noteable]

April 16 (Reuters) - Merck & Co has agreed to acquire Prometheus Biosciences Inc. for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday, which further supports the long-standing position that Big Pharma is seeking to acquire "bolt-on" assets that average around US$10 Billion for 2023, at a time when Big Pharma is facing an

[Noteable]

In January 2023, Riovant's CEO Matt Gline stated “Big pharma companies, although they are clearly focused and constrained on being efficient with R&D spend, are in many cases swimming in cash right now. Capital is not a concern for big pharma companies.“  Then as I posted here in March 2023 -  “ Inflation is a driver for Big Pharma companies like Pfizer,

[Noteable]

According to Drug Discovery October 4, 2023 - An analysis of the pharma and biotech M&A data from 2018 to early October 2023 deal activity jumped to an average of roughly 6 deals per month. For context, when interest rates ranged from 1.4% to 2.4% from 2018 to 2019, the industry averaged roughly 2 deals per month. While there was a relative increase in M&A volume

[Noteable]

As KPMG reported in its Biopharm Deal Trends Outlook for 2023, and continues to still apply, “ Currently there is a dearth of available quality mid and late-stage assets in oncology “ .  https://kpmg.com/kpmg-us/content/dam/kpmg/pdf/2023/biopharma-deal-trends-outlook.pdf